UBS lowered the firm’s price target on Acuren (TIC) to $11.50 from $12 and keeps a Neutral rating on the shares. Acuren announced an agreement to acquire NV5 (NVEE), which has good strategic appeal, though Q1 EBITDA was softer amid stronger revenue, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIC: